deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT04474470

A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion At the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

Sponsor: TyrNovo Ltd.

Conditions Colorectal Adenocarcinoma Head and Neck Cancer Metastatic Solid Tumor Recurrent Solid Tumor Solid Tumor, Adult Squamous Cell Carcinoma of Head and Neck
Interventions NT219 NT219 and ERBITUX® - Dose Escalation NT219 and ERBITUX® - Expansion
Updated 19 times since 2020 Last updated: Sep 15, 2024 Started: Sep 3, 2020 Primary completion: May 8, 2024 Completion: May 8, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Colorectal Adenocarcinoma and Head and Neck Cancer and is currently completed. TyrNovo Ltd. leads this study, which shows 19 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Jan 2023 · 7 months · monthly snapshot~Jan 2023 – ~Dec 2023 · 11 months · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~Jun 2024 · 3 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Oct 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  3. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 14 earlier versions

  1. Mar 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Dec 2023 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jan 2023 — Dec 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2022 — Jan 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  11. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  12. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  13. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  14. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • TyrNovo Ltd.
Data source: Purple Biotech Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations